Marc E. Agronin

2 months ago | medcentral.com | Marc E. Agronin |Ivan Oransky |Charles Piller |Greg Sackuvich

The oral NMDA receptor antagonist/sigma-1 receptor agonist AXS-05 significantly delayed and prevented Alzheimer’s disease agitation relapse compared with placebo, according to results of the ACCORD-2 trial presented at the 2025 American Academy of Neurology annual meeting held in San Diego this week. “These results support the use of AXS-05 as a safe and effective treatment for AD agitation,” said George Grossberg, MD, of Saint Louis University School of Medicine, St. Louis, MO.

Mar 14, 2025 | medcentral.com | Marc E. Agronin |Marcia Frellick |Avery Hurt |Alexis Pellek

The US FDA has approved the thrombolytic drug tenecteplase (TNKase) for treatment of acute ischemic stroke. The medication was already approved for use in ST-elevation myocardial infarction (STEMI). Yasmin Aziz, MD, assistant professor of clinical neurology and rehabilitation medicine at the University of Cincinnati College of Medicine, spoke with MedCentral to offer some thoughts on how this new approval will affect clinical practice.

Apr 15, 2024 | advisorstream.com | Marc E. Agronin |Joe Carpenter

By Marc E. Agronin April 15, 2024 For as long as I’ve been practicing medicine, Alzheimer’s disease has been, essentially, a death sentence. You give the diagnosis, and you prepare the patient and the family for the worst. Until now. Consider one of my patients at the memory-disorder clinic that I run. She’s 68 years old and not ready to retire.

Jul 6, 2023 | neurologylive.com | Marc E. Agronin

Jul 6, 2023 | neurologylive.com | Marc E. Agronin